Question 1

MRK vs RARE: which stock scores better overall?

Accepted Answer

Based on Q·Score, Merck & Company, Inc. (MRK) scores 6.7/10 versus Ultragenyx Pharmaceutical Inc. (RARE) at 5.2/10. The Q·Score measures five dimensions: Quality, Value, Growth, Safety, and Momentum. For informational purposes only — not financial advice.

Question 2

Which has better revenue growth: MRK or RARE?

Accepted Answer

Ultragenyx Pharmaceutical Inc. (RARE) scores higher on Growth (6.5/10 vs 6.2/10). Merck & Company, Inc. reports revenue growth (4.9% YoY) while Ultragenyx Pharmaceutical Inc. reports (25.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Question 3

Is MRK or RARE more attractively valued?

Accepted Answer

Merck & Company, Inc. (MRK) scores higher on Value (7.2/10 vs 6.9/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

Question 4

What do analysts say about MRK vs RARE?

Accepted Answer

There are 27 analysts covering MRK with a consensus price target of $129.74, and 20 analysts covering RARE with a consensus target of $53.35. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Question 5

Which is more profitable: MRK or RARE?

Accepted Answer

Merck & Company, Inc. (MRK) scores higher on Quality (6.2/10 vs 0.2/10). Net profit margin: MRK at 13.6%, RARE at -85.4%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Question 6

Which has stronger financial health: MRK or RARE?

Accepted Answer

Merck & Company, Inc. (MRK) scores higher on Financial Health (7/10 vs 5.9/10). Market beta: MRK at 0.28, RARE at 0.25. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

Question 7

What are the market caps of MRK and RARE?

Accepted Answer

Merck & Company, Inc. (MRK) has a market capitalisation of $277.0B, while Ultragenyx Pharmaceutical Inc. (RARE) has a market cap of $2.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Question 8

Do MRK or RARE pay dividends?

Accepted Answer

MRK pays a dividend yield of 3.03%, while RARE does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.

Merck & Company, Inc. vs Ultragenyx Pharmaceutical Inc. — Stock Comparison

Q·Score Breakdown

Analyst Consensus

Fundamentals